Published in Hepatitis Weekly, November 13th, 2000
A clinical trial conducted in Rotterdam, The Netherlands, has eliminated plasma kinetics as one reason why some HBV patients do not completely respond to lamivudine therapy.
In describing the pharmacokinetics of lamivudine therapy in HBV patients to attendees at the 29th Annual Meeting of the American College of Clinical Pharmacology, held in Chicago, Illinois, Arnold G. Vulto et al. said, "A typical response is a rapid decline with 1-3 log...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
Source: Hepatitis Weekly (2000-11-13)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.